Skip to main content

Clinical trials explorer

Filter by cancer type, molecular target, phase, and recruitment status.

← Module home

Loading filters…

Pioneering clinical study — approach supported by longer-term resultsPhase IINCT04165772

Primary analysis

Can rectal cancer be treated without surgery in some patients?

Rectum

NEJM 2025: complete clinical response in 49/49 who completed treatment (complete clinical response ≠ cure)

Pioneering phase II; NEJM 2025 complete clinical response in 49/49 who completed treatment. Single-arm; AZUR-1 is a separate confirmatory trial.

Newly reported results · Registry checked: 2026-10-29

Phase III · Positive results published · US-approvedPhase IIINCT06625320

Primary analysis · FDA approval — 26 August 2026 (US). Indication: metastatic pancreatic adenocarcinoma in adults after ≥1 prior systemic therapy or who are not candidates for multiagent systemic therapy. Label is not limited to RAS mutation. Türkiye license/SGK are separate.

Does daraxonrasib prolong survival in previously treated metastatic pancreatic cancer?

Pancreas

Median overall survival 13.2 vs 6.7 mo (overall population) · US approval; Türkiye separate

Positive phase III overall survival/progression-free survival (NEJM); US-approved. Access in Türkiye separate. RAS G12 primary; overall population and label read separately.

Practice-entering research · Registry checked: 2026-10-29

Phase III · Positive results published · US-approvedPhase IIINCT02912559

Primary analysis · FDA regular approval — 8 October 2026 (US). Atezolizumab (± subcutaneous hyaluronidase formulation) + fluoropyrimidine/oxaliplatin; adjuvant stage III dMMR colon. Türkiye license/SGK separate.

ATOMIC — Adding immunotherapy to chemotherapy after surgery in colon cancer

Colon

Primary card: Colon Landmark Atlas · Emerging is a bridge

Phase III disease-free survival benefit (NEJM); US-approved. overall survival not settled. Access in Türkiye separate. Primary card: Colon Landmark Atlas.

Practice-entering research · Registry checked: 2026-11-03

Phase III · Positive results published · US-approvedPhase IIINCT03504397

Final analysis · FDA approval — 18 October 2024 (US). Zolbetuximab-clzb (Vyloy) + fluoropyrimidine/platinum chemotherapy; CLDN18.2-positive, HER2-negative unresectable locally advanced or metastatic gastric/GEJ. Türkiye license/SGK separate.

SPOTLIGHT — Targeted zolbetuximab therapy in advanced gastric cancer

Gastric / esophageal

Primary card: Gastric Landmark Atlas · Emerging is a bridge

Phase III progression-free survival/overall survival benefit (Lancet); US-approved. Access in Türkiye separate. Primary card: Gastric Landmark Atlas.

Practice-entering research · Registry checked: 2026-11-03

Phase III · Positive results published · US-approvedPhase IIINCT04704934

Primary analysis · T-DXd is FDA-approved in the US for HER2-positive gastric/GEJ (initial approval based on DESTINY-Gastric01, 2021). DESTINY-Gastric04 strengthens comparative OS evidence; it is not itself a new licensing claim. Türkiye license/SGK separate.

DESTINY-Gastric04 — Second-line T-DXd in HER2-positive advanced gastric cancer

Gastric / esophageal

Primary card: Gastric Landmark Atlas · Emerging is a bridge

2L T-DXd overall survival 14.7 vs 11.4 mo (hazard ratio 0.70). ILD critical. FDA label origin DG01; DG04 comparative evidence. Primary card: Gastric Landmark.

Practice-entering research · Registry checked: 2026-11-01

Phase III · Positive results published · US-approvedPhase IIINCT02989857

Final analysis · FDA approval — 25 August 2021 (US). Tibsovo (ivosidenib); previously treated, IDH1-mutant locally advanced or metastatic cholangiocarcinoma. Türkiye license/SGK separate.

ClarIDHy — Targeted ivosidenib therapy in advanced biliary tract cancer

Biliary tract

Primary card: Biliary tract cancer Landmark Atlas · Emerging is a bridge

Phase III progression-free survival benefit (Lancet Oncol); FDA 25 Aug 2021. overall survival complicated by crossover. Primary card: Biliary Landmark Atlas.

Practice-entering research · Registry checked: 2026-11-03

Phase III · Positive results published · US-approvedPhase IIINCT04039607

Final analysis · FDA approval — 11 April 2025 (US). Opdivo + Yervoy; first-line unresectable/metastatic HCC. Türkiye licensing must be verified separately.

CheckMate 9DW — Dual immunotherapy in advanced liver cancer

Liver (HCC)

1L nivo+ipi overall survival 23.7 vs 20.6 mo (hazard ratio 0.79); 4y follow-up hazard ratio 0.78. TRAE deaths 12 vs 3. FDA 11 Apr 2025. Child-Pugh A.

Practice-entering research · Registry checked: 2026-11-04

Scientific discovery dossierExperimental discoveries

RAS(ON) tri-complex pharmacology — preclinical discovery basis

Pancreas · Multiple / solid tumors

Discovery dossier: RAS(ON) preclinical concept underpinning clinical programs — not a care standard.

Experimental models: Cell lines and animal models (clinical translation is on separate cards).

Translational distance: Human clinical benefit cannot be inferred here. Clinical: RMC-6236-001, RASolute 302, elironrasib/daraxonrasib.

Not a clinical trial or treatment option.

Scientific discovery dossierExperimental discoveriesDOI 10.1002/anie.202317578

Photo-controlled calcium storm — Ca²⁺ overload in tumor cells

Multiple / solid tumors

Discovery dossier: light-triggered endogenous Ca²⁺ storm. No human clinical efficacy evidence.

Experimental models: Tumor cell cultures; injectable HA-coated mesoporous silica nanomodulator; tumor regression after NIR irradiation reported in tumor-bearing mice.

Translational distance: Not a human clinical trial or approved therapy. Selectivity, systemic toxicity, and translation into surgical oncology practice are unproven.

Not a clinical trial or treatment option.

Scientific discovery dossierExperimental discoveriesDOI 10.1016/j.bbamcr.2014.02.012

SOCE / STIM1–ORAI1 — apoptotic resistance in pancreatic adenocarcinoma

Pancreas

Discovery dossier: STIM1/ORAI1 SOCE contributes to apoptotic resistance in PDAC cells — not a clinical test.

Experimental models: Pancreatic adenocarcinoma cell lines / in vitro SOCE measurements.

Translational distance: Not a validated clinical predictive test or approved drug target. Does not change surgical/adjuvant decisions.

Not a clinical trial or treatment option.

Scientific discovery dossierExperimental discoveriesDOI 10.21037/tcr-2024-2563

SOCE_Score — research biomarker (neuroblastoma RNA-seq)

Multiple / solid tumors

Discovery dossier: SOCE_Score studied in neuroblastoma datasets — not a clinic-validated predictive test.

Experimental models: Multiple neuroblastoma RNA-seq datasets; claimed validation across cohorts; CMap drug-repurposing hypothesis.

Translational distance: Not a GI surgical oncology standard. Must not be presented as an approved predictive test. Needs medical review.

Not a clinical trial or treatment option.

Scientific discovery dossierExperimental discoveriesDOI 10.1002/emmm.201302989

STIM1/STIM2 — CD8+ T-cell antitumor immunity

Multiple / solid tumors

Discovery dossier: SOCE is critical for CD8+ antitumor immunity — not a human treatment protocol.

Experimental models: Conditional knockout mice; in vivo tumor-immunity experiments.

Translational distance: Generates immunotherapy-combination hypotheses; no clinical SOCE-inhibitor indication.

Not a clinical trial or treatment option.

Scientific discovery dossierExperimental discoveriesDOI 10.1016/j.biopha.2022.114074

TRP channels, calcium homeostasis, and metastasis — discovery dossier

Multiple / solid tumors

Discovery dossier (not one NCT): TRP–Ca²⁺–metastasis links are cancer-type specific; no claim that organ metastasis is ‘solved’.

Experimental models: Cell migration/invasion; xenograft/experimental metastasis mouse models; clinical cohort correlations (correlation ≠ causation).

Translational distance: A composite of multiple papers — not one clinical trial. Does not claim organ-specific metastasis mechanisms are fully solved.

Not a clinical trial or treatment option.

Phase III · Positive results published · US-approvedPhase IIINCT04008030

Final analysis · FDA approval — 8 April 2025 (US). Nivolumab + ipilimumab; MSI-H/dMMR unresectable or metastatic colorectal cancer (≥12 years). Same action converted prior accelerated nivo monotherapy approval to regular (after fluoropyrimidine/oxaliplatin/irinotecan). Türkiye licensing must be verified separately.

CheckMate 8HW — Dual immunotherapy in metastatic colon and rectal cancer

Colon · Rectum

Primary card: Colon Landmark Atlas · Emerging is a bridge

1L nivo+ipi vs chemo: progression-free survival hazard ratio 0.21; final overall survival hazard ratio 0.37. All-lines nivo+ipi vs nivo: progression-free survival hazard ratio 0.62; overall survival hazard ratio 0.61. FDA 8 Apr 2025. Primary card: Colon Landmark.

Practice-entering research · Registry checked: 2026-11-04

Becoming establishedPhase IIINCT05152147

Primary analysis · US FDA approved two first-line zanidatamab-containing regimens for HER2-positive advanced gastric, GEJ, or esophageal adenocarcinoma on 25 August 2026. Eligibility differs by HER2 IHC/ISH status. Turkey licensing and reimbursement were not verified in this assessment.

HERIZON-GEA-01 — zanidatamab ± tislelizumab + chemo (HER2+ GEA)

Gastric / esophageal

NEJM May 2026: progression-free survival 12.4 vs 8.1 mo (zanidatamab±tislelizumab). Separate from DESTINY-Gastric04 / SPOTLIGHT.

Newly reported results · Registry checked: 2026-10-29

Research areaEmerging treatment technologiesPriority: very high

Personalized mRNA cancer vaccines

Melanoma · Pancreas · Multiple / solid tumors

Research area: personalized mRNA vaccines. KEYNOTE-942, V940 phase III, and pancreas vaccine cards are listed separately underneath.

Evidence level: Randomized phase IIb results in melanoma plus phase III confirmation trials; early clinical in pancreas.

Not a single trial · 3 linked records

Research areaEmerging treatment technologiesPriority: very high

PROTACs — targeted protein degradation

Pancreas · Multiple / solid tumors

Research area: protein degradation. Setidegrasib (KRAS G12D) clinical card underneath; separate from classic inhibitor cards.

Evidence level: 2026 phase I clinical activity signal for KRAS G12D degrader setidegrasib (ASP3082) in NEJM; not standard care.

Not a single trial · 1 linked records

Research areaEmerging treatment technologiesPriority: very high

Bispecific antibody–drug conjugates (BsADCs)

Gastric / esophageal · Biliary tract · Multiple / solid tumors

Research area: BsADCs. BL-B01D1 esophagus/biliary phase III cards underneath; zanidatamab is not an ADC.

Evidence level: Some molecules in phase III / regional programs; izalontamab brengitecan (BL-B01D1) as an example. Not all BsADCs are equivalent.

Not a single trial · 2 linked records

Research areaEmerging treatment technologiesPriority: high

Armored CAR-T — solid tumors

Multiple / solid tumors

Research area: armored CAR-T. Early-phase ARMADA example underneath; do not conflate with hematologic CAR-T.

Evidence level: Mostly early clinical (phase I) in solid tumors. Hematologic CAR-T success does not automatically transfer.

Not a single trial · 1 linked records